🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

RUBICON RESEARCH LIMITED RUBICON NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.rubicon.co.in
Company Profile ↓
₹1,465.60
+133.30% 1Y
Mkt Cap₹24,145.81 Cr
P/E95.73
P/B18.39
52W High₹1,465.60
52W Low₹577.25
Book Value₹78.23
EPS (TTM)₹15.31

Company Overview

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 24.3%.

Consistent Profit Growth

Net profit has compounded at 38.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 36.6% CAGR over the past five years.

Healthy Margins

Operating margin of 20.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.24.

Recent Developments

  • Mar 2026 Revenue of ₹1,753.96 Cr (+36.6% YoY); net profit ₹246.74 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +36.6%, earnings +171.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 36.6%, profit CAGR 38.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:36.57%
1 Year:36.57%

Compounded Profit Growth

5 Years:38.17%
1 Year:171.14%

Stock Price Performance

1 Year:+133.30%
6 Months:+111.52%
3 Months:+78.45%
1 Month:+9.02%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 100% of range
₹577.25 ₹1,465.60
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)69.20 · Neutral
Price Performance
1M+9.02%
3M+78.45%
6M+111.52%
1Y+133.30%
Valuation vs Sector

P/E of 95.73 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 24.3%.
  • Compounding revenue at 36.6% over 5 years.
  • Profit CAGR of 38.2% over 5 years.

CONS

  • Trading at a high P/E of 95.7.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
95.73
Industry PE
39.97
Forward P/E
52.72
PEG Ratio
-
Book Value
₹78.23
Price to Book
18.39
P/S
13.51
EV/EBITDA
59.12
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
36.57%
Profit 5Y
38.17%
Revenue (YoY)
36.57%
Earnings (YoY)
171.14%

Profitability & Returns

ROCE
24.33%
ROE
19.14%
ROA
10.60%
Profit Margin
14.07%
Op Margin
20.24%
Gross Margin
68.30%
EPS (Latest Qtr)
₹4.60
EPS (TTM)
₹15.31

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
1.14
Current Ratio
2.01
Debt
₹311.01 Cr
Total Assets
₹2,326.71 Cr
Current Assets
₹1,681.81 Cr
Working Capital
₹845.94 Cr

Ownership

Promoter Holding
77.68%
Chg in Prom Hold
0.02%
FII / Inst Holding
12.02%
Chg in FII Hold
0.16%

Financial Snapshot

Enterprise Value
₹24,145.81 Cr
Total Revenue (TTM)
₹1,753.96 Cr
EBITDA
₹407.96 Cr
Free Cash Flow
₹-24.12 Cr
Operating Cash Flow
₹205.05 Cr
Shares Outstanding
₹16.48 Cr
Gross Margin
68.30%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RUBICON RUBICON RESEARCH LIMITED NSEPHARMA 1,465.60 95.73 ₹24,145.81 Cr 0.00% 24.33% 19.14% 36.57% 38.17%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 296.00 Cr313.40 Cr358.15 Cr352.00 Cr412.00 Cr475.53 Cr513.91 Cr
Cost of Revenue -98.84 Cr111.59 Cr--157.26 Cr169.31 Cr
Gross Profit -214.56 Cr246.55 Cr--318.27 Cr344.61 Cr
Operating Expenses 234.00 Cr154.08 Cr183.74 Cr273.00 Cr318.00 Cr221.70 Cr238.17 Cr
Operating Income 54.00 Cr60.48 Cr62.81 Cr69.00 Cr82.00 Cr96.57 Cr106.44 Cr
EBITDA 62.00 Cr70.39 Cr72.57 Cr79.00 Cr94.00 Cr111.91 Cr121.31 Cr
Interest Expense 7.00 Cr7.82 Cr11.85 Cr11.00 Cr11.00 Cr9.77 Cr10.36 Cr
Pretax Income 49.00 Cr53.15 Cr51.06 Cr60.00 Cr72.00 Cr90.59 Cr98.69 Cr
Tax Provision 14.70 Cr15.08 Cr14.81 Cr16.20 Cr18.00 Cr17.79 Cr21.90 Cr
Net Income 34.00 Cr38.07 Cr36.24 Cr43.00 Cr54.00 Cr72.80 Cr76.78 Cr
Diluted EPS 2.272.312.202.813.494.414.60

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 263.00 Cr315.00 Cr314.00 Cr394.00 Cr854.00 Cr1,284.27 Cr1,753.96 Cr
Cost of Revenue -----375.39 Cr556.05 Cr
Gross Profit -----908.88 Cr1,197.90 Cr
Operating Expenses 182.00 Cr223.00 Cr353.00 Cr375.00 Cr699.00 Cr681.21 Cr842.93 Cr
Operating Income 63.00 Cr63.00 Cr-73.00 Cr-18.00 Cr116.00 Cr227.67 Cr354.98 Cr
EBITDA 81.00 Cr92.00 Cr-39.00 Cr18.00 Cr155.00 Cr267.89 Cr407.96 Cr
Interest Expense 6.00 Cr9.00 Cr10.00 Cr19.00 Cr31.00 Cr36.78 Cr42.17 Cr
Pretax Income 74.00 Cr63.00 Cr-66.00 Cr-11.00 Cr103.00 Cr-320.53 Cr
Tax Provision 24.42 Cr32.13 Cr-1.32 Cr-5.83 Cr12.36 Cr-73.80 Cr
Net Income 49.00 Cr31.00 Cr-67.00 Cr-17.00 Cr91.00 Cr-246.74 Cr
Diluted EPS 97.4660.53-132.39-33.315.98-15.31

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 430.00 Cr538.00 Cr560.00 Cr750.00 Cr1,109.00 Cr1,451.00 Cr2,326.71 Cr
Current Assets ------1,681.81 Cr
Cash & Equivalents ------185.65 Cr
Inventory ------728.99 Cr
Receivables ------508.71 Cr
Total Liabilities ------1,037.89 Cr
Current Liabilities ------835.87 Cr
Long Term Debt ------143.02 Cr
Total Debt 30.00 Cr93.00 Cr175.00 Cr320.00 Cr425.00 Cr418.00 Cr311.01 Cr
Total Equity 340.00 Cr374.00 Cr305.00 Cr286.00 Cr385.00 Cr541.00 Cr1,288.82 Cr
Shares Outstanding ------16.48 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 5.00 Cr62.00 Cr-63.00 Cr-75.00 Cr21.00 Cr-205.05 Cr
Investing Cash Flow -84.00 Cr-46.00 Cr-46.00 Cr-32.00 Cr-68.00 Cr--409.72 Cr
Financing Cash Flow 80.00 Cr52.00 Cr63.00 Cr123.00 Cr44.00 Cr-283.07 Cr
Capital Expenditure -59.00 Cr-72.00 Cr-54.00 Cr-44.00 Cr-56.00 Cr--229.17 Cr
Free Cash Flow -54.00 Cr-10.00 Cr-117.00 Cr-119.00 Cr-35.00 Cr--24.12 Cr
Net Change in Cash 1.00 Cr67.00 Cr-45.00 Cr16.00 Cr-4.00 Cr-78.39 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----70.8%68.3%
Operating Margin % 24.0%20.0%-23.2%-4.6%13.6%17.7%20.2%
Net Margin % 18.6%9.8%-21.3%-4.3%10.7%-14.1%
ROE % 14.4%8.3%-22.0%-5.9%23.6%-19.1%
ROCE % ------23.8%

Shareholding Pattern

Insiders
77.68%
Institutions
12.02%
Public Float
53.88%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RUBICON

Google News Sat, 30 May 2026

Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOT09vVXlzcVlwZ0pvaExNRXgzeGQyZVQ3M0VTYjJPSEp0b0FmbG1zclAxSkZucnNEa1NSd2xJQS05TEZiUGVXMXd4QU1yNEYwR2EybUlhbl9mS0pzZDBScmhMZk9YamlZcjNGZjU4Y1ZpYVBKUDUwY1NTTHVvS01obURJUlRFc3QxdjB0X1…

Google News Wed, 29 Apr 2026

Jeep says 1 million Rubicon off-road models have sold worldwide - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQdEZDTjBFRmRFcUdtaUJGczZPMm9XbVF5b2IzZ09MbzRZQ09xWjdzMzd2a1JkcjVwaFpuLUJhRFpCNEozM3hSNVk5ZWV3T0duTTMyZjU1OVczSVJ1Z3N5bU55cHFxLW9xVlV6TTJhZ1Z0ckRMS21PcmRjdGZhS0FWdExzcjEyX1lMYjhfc1…

Google News Sun, 31 May 2026

Is Privia Health Group (PRVA) a "Smart Money" Bet After Rubicon Founders' Massive Stake Increase - Kavout | AI

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNUmtpX2Z2MVdKX1VpeXg2eGk0T0RvVkJiaXpRSHItMDg1OHlFX0FMUHhkN2tzWl9SelZmWHNodW9IUHNBelM1TnZZay1SdzRGNXI1WkJYTTcxX2NfV2xwOHdIY3phcnpzTWNmNEJXbWd5UGVUSVVjNUZiQzIyQ0FOQUQ4QXJsSzh0RGFhZX…

Google News Sun, 05 Jul 2026

Price to earnings forward of Rubicon Technology, Inc. – SWB:39YA - TradingView

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQd2psc1JSZmQ3MVNxemxMSzdNd2RFeWxYYUkxaW53Uml1OS11NW5KcWxZbG4tR29GMnJIdUFWdXFsZ29QNkd6S2k3UWtBLVRYd0Q5WGdiR2xoRnFpSHpPLU9URkFWejExQU1SOWJCZU5QckhCWHgyZFFwaTRBYTNHbW5HbmEtd1dxQk5hWW…

Google News Mon, 10 Nov 2025

Rubicon Organics Secures $4M in Financing to Support Strategic Growth Initiatives - Cannabis Business Times

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRnVNVEZKV1dVSGVHaVBVTGZXOVowcVdCeXBpSDhHQzh5bnljaFlkTUpYUS1veGg2SkYyMG9aN24zQkFMWjR4ZWY5S2k4cm1Vd09JY2NMb1Jlb2l4NUMxcTlsR2hGYUJhMDZ0TUFzQmsweS16QURyQWptMy0yQWxOY25lRE9EOFpBU1lmTU…

Google News Mon, 29 Jun 2026

ProPetro Holding: Hidden Data Center Bet Is Getting Traction - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOX1BhZEJVRTktY2J4aVRkUm9xOUVwZGtmNWxacFVJelFWUUI2NXFEU3dYVnJSR2RLdGVqZXp1MmdiOWNHWUhPekVWM0xxZDlHLUJPQmlhR3o0QVk2aWw0SDRGTnJYSVRCekdlb3VxUS1QRk9Yd1dPajJ2eXZwQnRxUHVFdUNLYXcxTWdKan…

RUBICON — Frequently Asked Questions

What is the current share price of RUBICON RESEARCH LIMITED (RUBICON)?

As of 2026-07-15 09:52 IST, RUBICON RESEARCH LIMITED (RUBICON) trades at ₹1,465.60 on NSE. Its 52-week range is ₹577.25 to ₹1,465.60.

What is the market capitalisation of RUBICON?

RUBICON RESEARCH LIMITED (RUBICON) has a market capitalisation of ₹24,145.81 Cr on NSE.

What is the P/E ratio of RUBICON?

RUBICON trades at a trailing price-to-earnings (P/E) ratio of 95.73. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 18.39.

What is the return on equity (ROE) of RUBICON?

RUBICON has a return on equity (ROE) of 19.14%. Its return on capital employed (ROCE) is 24.33%.

Is RUBICON a good stock to buy?

This page provides a data-driven analysis of RUBICON RESEARCH LIMITED (RUBICON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space